4 results on '"Jia, Hong-Yu"'
Search Results
2. Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.
- Author
-
Zeng LY, Lian JS, Chen JY, Jia HY, Zhang YM, Xiang DR, Yu L, Hu JH, Lu YF, Zheng L, Li LJ, and Yang YD
- Subjects
- Adolescent, Adult, Aged, Alanine Transaminase blood, Aspartate Aminotransferases blood, Biomarkers blood, China, Cross-Sectional Studies, DNA, Viral blood, Female, Hepatitis B e Antigens blood, Hepatitis B virus genetics, Hepatitis B, Chronic blood, Hepatitis B, Chronic immunology, Humans, Male, Middle Aged, Prognosis, Prospective Studies, Time Factors, Viral Load, Young Adult, Hepatitis B Surface Antigens blood, Hepatitis B virus immunology, Hepatitis B, Chronic diagnosis
- Abstract
Aim: To determine the baseline hepatitis B surface antigen (HBsAg) levels during the different phases of chronic hepatitis B (CHB) patients in China., Methods: Six hundred and twenty-three hepatitis B virus or un-infected patients not receiving antiviral therapy were analyzed in a cross-sectional study. The CHB patients were classified into five phases: immune-tolerant (IT, n = 108), immune-clearance (IC, n = 161), hepatitis B e antigen negative hepatitis (ENH, n = 149), low-replicative (LR, n = 135), and liver cirrhosis (LC, n = 70). HBsAg was quantified (Abbott ARCHITECT assay) and correlated with hepatitis B virus (HBV) DNA, and serum alanine aminotransferase/aspartate aminotransferase (ALT/AST) in each phase of CHB was also determined., Results: Median HBsAg titers were different in each phase of CHB (P < 0.001): IT (4.85 log10 IU/mL), IC (4.36 log10 IU/mL), ENH (2.95 log10 IU/mL), LR (3.18 log10 IU/mL) and LC (2.69 log10 IU/mL). HBsAg titers were highest in the IT phase and lowest in the LC phase. Serum HBsAg titers showed a strong correlation with HBV viral load in the IC phase (r = 0.683, P < 0.001). No correlation between serum HBsAg level and ALT/AST was observed., Conclusion: The mean baseline HBsAg levels differ significantly during the five phases of CHB, providing evidence on the natural history of HBV infection. HBsAg quantification may predict the effects of immune-modulator or oral nucleos(t)ide analogue therapy.
- Published
- 2014
- Full Text
- View/download PDF
3. HBsAg levels in HBeAg-positive chronic hepatitis B patients with different immune conditions.
- Author
-
Zhang YM, Yang YD, Jia HY, Zeng LY, Yu W, Zhou N, and Li LJ
- Subjects
- Acute-On-Chronic Liver Failure blood, Acute-On-Chronic Liver Failure immunology, Adult, Biomarkers blood, Cross-Sectional Studies, DNA, Viral blood, Female, Humans, Immune Tolerance, Liver virology, Male, Sex Factors, Viral Load, Hepatitis B Surface Antigens blood, Hepatitis B e Antigens blood, Hepatitis B, Chronic blood, Hepatitis B, Chronic immunology
- Abstract
Aim: To investigate hepatitis B surface antigen (HBsAg) levels in patients with HBeAg-positive chronic hepatitis B (CHB) and different immune conditions., Methods: HBeAg-positive CHB patients with different immune conditions were enrolled in this cross-sectional study. These patients were grouped according to the following criteria: immune-tolerant patients, IT group; patients with a mild immune response in the immune clearance phase, IC-Mild group; and patients with a dramatic immune response in the immune clearance phase and exhibiting acute on chronic liver failure (ACLF), ACLF group. All these patients had not previously received antiviral therapy and were enrolled at a pre-settled ratio of 2:2:1. Serum HBsAg levels and the correlation between serum HBsAg level and serum hepatitis B virus (HBV) DNA level were evaluated in these groups., Results: In total, 180 HBeAg-positive CHB patients [IT group (n = 72), IC-Mild group (n = 72), and ACLF group (n = 36)] were enrolled in this study. The median serum HBsAg levels varied among the groups (P < 0.001): IT, 4.86 log10 IU/mL; IC-Mild, 3.97 log10 IU/mL; and ACLF, 3.57 log10 IU/mL. Serum HBsAg level showed a moderate positive correlation with serum HBV-DNA level in the IC-Mild group (r = 0.60, P < 0.001), but exhibited a weaker correlation in the IT (r = 0.52, P < 0.001) and ACLF groups (r = 0.51, P = 0.001). The ratio of HBsAg/HBV DNA did not differ significantly among the IT, IC-Mild, and ACLF groups (medians: 0.56, 0.55, and 0.56, respectively; P = 0.179)., Conclusion: Serum HBsAg levels varied significantly in HBeAg-positive patients with different immune conditions. These findings may have important implications for understanding the immune clearance of HBV in HBeAg-positive CHB patients.
- Published
- 2014
- Full Text
- View/download PDF
4. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis.
- Author
-
Lian JS, Zeng LY, Chen JY, Jia HY, Zhang YM, Xiang DR, Yu L, Hu JH, Lu YF, Zheng L, Li LJ, and Yang YD
- Subjects
- Adenine adverse effects, Adenine therapeutic use, Adult, Alanine Transaminase blood, Analysis of Variance, Antiviral Agents adverse effects, Biomarkers blood, Chi-Square Distribution, China, DNA, Viral blood, Drug Therapy, Combination, Female, Guanine adverse effects, Guanine therapeutic use, Hepatitis B complications, Hepatitis B diagnosis, Hepatitis B mortality, Hepatitis B e Antigens blood, Hepatitis B virus genetics, Hepatitis B virus growth & development, Hepatitis B virus immunology, Humans, Lamivudine adverse effects, Liver Cirrhosis diagnosis, Liver Cirrhosis mortality, Liver Cirrhosis virology, Male, Middle Aged, Organophosphonates adverse effects, Prospective Studies, Time Factors, Treatment Outcome, Adenine analogs & derivatives, Antiviral Agents therapeutic use, Guanine analogs & derivatives, Hepatitis B drug therapy, Hepatitis B virus drug effects, Lamivudine therapeutic use, Liver Cirrhosis drug therapy, Organophosphonates therapeutic use
- Abstract
Aim: To compare efficacy of combined lamivudine (LAM) and adefovir dipivoxil (ADV) therapy with that of entecavir (ETV) monotherapy for hepatitis B virus (HBV)-related decompensated liver cirrhosis., Methods: A total of 120 naïve patients with HBV-related decompensated cirrhosis participated in this study. Sixty patients were treated with combined LAM and ADV therapy (LAM + ADV group), while the other 60 were treated with ETV monotherapy (ETV group) for two years. Tests for liver and kidney function, alpha-fetoprotein, HBV serum markers, HBV DNA load, prothrombin time (PT), and ultrasonography or computed tomography scan of the liver were performed every 1 to 3 mo. Repeated measure ANOVA and the χ(2) test were performed to compare the efficacy, side effects, and the cumulative survival rates at 48 and 96 wk., Results: Forty-five patients in each group were observed for 96 wk. No significant differences in HBV DNA negative rates and alanine aminotransferase (ALT) normalization rates at weeks 48 (χ(2) = 2.12 and 2.88) and 96 (χ(2) = 3.21 and 3.24) between the two groups were observed. Hepatitis B e antigen seroconversion rate in the LAM + ADV group at week 96 was significantly higher in the ETV group (43.5% vs 36.4%, χ(2) = 4.09, P < 0.05). Viral breakthrough occurred in 2 cases (4.4%) by week 48 and in 3 cases (6.7%) by week 96 in the LAM + ADV group, and no viral mutation was detected. In the ETV group, viral breakthrough occurred in 1 case (2.2%) at the end of week 96. An increase in albumin (F = 18.9 and 17.3), decrease in total bilirubin and in ALT (F = 16.5, 17.1 and 23.7, 24.8), reduced PT (F = 22.7 and 24.5), and improved Child-Turcotte-Pugh and the model for end-stage liver disease scores (F = 18.5, 17.8, and 24.2, 23.8) were observed in both groups. The cumulative rates of mortality and liver transplantation were 16.7% (10/60) and 18.3% (11/60) in the LAM + ADV and ETV groups, respectively., Conclusion: Both LAM + ADV combination therapy and ETV monotherapy can effectively inhibit HBV replication, improve liver function, and decrease mortality.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.